Press release - 31/01/2017 Background Suppression for Super-resolution Light Microscopy Researchers of Karlsruhe Institute of Technology (KIT) have developed a new fluorescence microscopy method: STEDD (Stimulation Emission Double Depletion) nanoscopy produces images of highest resolution with suppressed background. The new method yields an enhanced image quality, which is advantageous when analyzing three-dimensional, densely arranged subcellular structures. STEDD, a further development of the STED method, is now presented in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/background-suppression-for-super-resolution-light-microscopy
Press release - 30/01/2017 ChemCon celebrates 20th anniversary ChemCon GmbH, service provider for custom development and custom manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals, based in the Innovationspark (innovations park) Freiburg, Germany, celebrates its 20th anniversary. On January 29 in 1997, Dr. Raphael Vogler (CEO) and Dr. Peter Gockel (CSO), both graduates from the Albert-Ludwigs-University Freiburg, signed the partnering contract to found ChemCon. Today they count 90…https://www.gesundheitsindustrie-bw.de/en/article/press-release/chemcon-celebrates-20th-anniversary
Article - 26/01/2017 Clinical cancer registration to improve patient treatment and care Germany records around 500,000 new cases of cancer every year. The number is steadily growing, mainly due to an ageing population that leads to an increased risk of cancer. The German government is planning to establish clinical cancer registries in all German states so that all cancer patients receive the best possible treatment. In Baden-Württemberg, all new cancer cases are already recorded. However, the data are still not as comprehensive as…https://www.gesundheitsindustrie-bw.de/en/article/news/clinical-cancer-registration-to-improve-patient-treatment-and-care
Article - 26/01/2017 Freiburg researchers transform skin cells into renal cells A team of researchers from Freiburg has used direct programming to successfully produce kidney-like cells very similar to natural renal tubular cells in terms of appearance and function. These cells are thus a promising alternative to kidney cells isolated from animals and cells differentiated from embryonic stem cells. The reprogrammed kidney cells can be used, for example, for pharmacological and toxicological tests and investigating the…https://www.gesundheitsindustrie-bw.de/en/article/news/freiburg-researchers-transform-skin-cells-into-renal-cells
Press release - 24/01/2017 Cancer Medications Learn to Hide The European Research Council awards Wilfried Weber an ERC Proof of Concept Grant. Wilfried Weber, Professor of Synthetic Biology at the University of Freiburg, has received a grant of roughly €150,000 for his project “Hide and Seek with Cancer Drugs” in which he is working to improve the drugs used in cancer treatment.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-medications-learn-to-hide
Dossier - 17/01/2017 Phytopharmaceuticals – fighting disease with natural substances Phytopharmaceuticals are herbal medicines whose efficacy is down to one or several plant substances or active ingredients. They have been used for treating diseases since time immemorial. This traditional knowledge is still the basis for many medicinal products made from plants or parts thereof. Herbal medicines have been produced in Baden-Württemberg for many generations. https://www.gesundheitsindustrie-bw.de/en/article/dossier/phytopharmaceuticals-fighting-disease-with-natural-substances
Article - 12/01/2017 Test system for skin damage caused by solar radiation Based on an accredited test method, the Fraunhofer IGB has developed an in vitro phototoxicity assay to measure the phototoxic potential of substances in medications and lotions used to protect the skin against environmental influences, which can become toxic when exposed to UV light. The assay uses human skin cells that have been grown into three-dimensional tissue as a human skin model. https://www.gesundheitsindustrie-bw.de/en/article/news/test-system-for-skin-damage-caused-by-solar-radiation
Company profile - 09/01/2017 Novaliq to develop innovative eye drop products A remedy is now available for people suffering from dry eye disease. Novaliq GmbH, a specialty pharmaceuticals company from Heidelberg, has developed a highly innovative technology platform for producing innovative drugs to eliminate common eye conditions that cause itching, burning and a feeling of pressure on the eye. The new drug delivery platform not only opens up groundbreaking new prospects for ophthalmology, but also for dermatology. https://www.gesundheitsindustrie-bw.de/en/article/news/novaliq-to-develop-innovative-eye-drop-products
Press release - 05/01/2017 Phenex receives 100 M USD Milestone Payment from Gilead Phenex Pharmaceuticals AG (Phenex) today announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674 targeting nonalcoholic steatohepatitis (NASH).https://www.gesundheitsindustrie-bw.de/en/article/press-release/phenex-receives-100-m-usd-milestone-payment-from-gilead
Press release - 05/01/2017 HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and coparion.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-gmbh-raises-9-million-in-a-series-a-financing-to-develop-kinase-inhibitors-for-the-treatment-of-acute-and-chronic-li
Article - 21/12/2016 For all types of tests: Signatope’s biomarker assays Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
Press release - 14/12/2016 Acousia Therapeutics Receives EUR 2.5 Million to Develop Innovative Therapy to Treat and Prevent Sensorineural Hearing Loss Acousia Therapeutics GmbH announced today the closing of a new investment round of EUR 2.5 million to finance research programs directed at the development of small molecules to treat sensorineural hearing loss and protecting sensory hair cells of the inner ear to prevent hearing loss in at-risk patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/acousia-therapeutics-receives-eur-25-million-to-develop-innovative-therapy-to-treat-and-prevent-sensorineural-hearing-loss
Press release - 14/12/2016 amcure Raises €6 Million in Series B Financing and Expands Advisory Board Eggenstein-Leopoldshafen – 14 December 2016: amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, today announced the closing of a Series B financing round amounting to a total of EUR 6 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-raises-6-million-in-series-b-financing-and-expands-advisory-board
Article - 14/12/2016 Transcranial brain stimulation to counteract chronic tiredness You may well be familiar with the ”leaden” feeling associated with lack of sleep. However, chronic tiredness lasting many months might be a sign of a serious disease. Dr. Lukas Frase, together with Prof. Dr. Christoph Nissen’s team at the Freiburg University Medical Center’s Department of Psychiatry and Psychotherapy, has come up with a method to help patients with abnormally high sleep needs. The method uses weak electrostimulation and has the…https://www.gesundheitsindustrie-bw.de/en/article/news/transcranial-brain-stimulation-to-counteract-chronic-tiredness
Press release - 13/12/2016 Early-diagnosis systems from Baden-Württemberg help prevent the spread of drug-resistant pathogens More and more bacteria are developing resistance to multiple antimicrobial drugs. These multidrug-resistant bacteria can impede the action of common antibiotics via mutations or DNA transfer. More than 30,000 people are infected every year with multidrug-resistant bacteria in German hospitals alone. This could be prevented with appropriate hygiene measures and innovative test systems. Innovative test systems that enable reliable and rapid…https://www.gesundheitsindustrie-bw.de/en/article/press-release/fruehdiagnostik-aus-baden-wuerttemberg-hilft-resistente-erreger-zu-stoppen
Article - 13/12/2016 Smart sensor technology from Ulm can do more than just breath analysis Detecting disease-specific molecules in human breath is technically feasible, but time-consuming and rather costly. "µbreath" could soon change this. The breath gas analysis device has all the necessary requirements for commercial success in the healthcare sector: it is compact, accurate, highly sensitive and fast. The chemist who developed µbreath, Prof. Boris Mizaikoff from Ulm University, and his partners are hoping to start…https://www.gesundheitsindustrie-bw.de/en/article/news/smart-sensor-technology-from-ulm-can-do-more-than-just-breath-analysis
Press release - 12/12/2016 Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-obtains-eib-debt-financing-totaling-up-to-eur-25-million-to-further-expand-its-diagnostic-platform
Press release - 30/11/2016 Takeda to invest more than 100 Million Euros in Dengue Vaccine Manufacturing plant in Germany Konstanz, Germany, November 29, 2016 and Osaka, Japan, November 30, 2016 – Takeda Pharmaceuticals Company Limited, (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. https://www.gesundheitsindustrie-bw.de/en/article/press-release/takeda-to-invest-more-than-100-million-euros-in-dengue-vaccine-manufacturing-plant-in-germany
Article - 22/11/2016 Research on the durability and longevity of artificial joints In Germany alone, several hundred thousand patients are given an artificial hip, knee or shoulder joint every year. Prof. Dr. Jan Philippe Kretzer and his team of researchers in the Laboratory of Biomechanics and Implant Research at the University Hospital in Heidelberg are studying what limits the longevity of implants and how durability can be improved. https://www.gesundheitsindustrie-bw.de/en/article/news/research-on-the-durability-and-longevity-of-artificial-joints
Expert interview - 14/11/2016 The great untapped potential of herbal medicines Baden-Württemberg is home to a large number of companies that produce herbal medicines, i.e. preparations made from plant extracts rather than pure compounds. In an interview with Dr. Ariane Pott from BIOPRO Baden-Württemberg, Professor Dr. Michael Wink, Director of the Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg, explains how these special extracts are placed on the market and how they differ from medicines…https://www.gesundheitsindustrie-bw.de/en/article/news/the-great-untapped-potential-of-herbal-medicines
Expert interview - 14/11/2016 Fighting diseases with plant-derived active compounds Herbal medicines have a long tradition in Germany. In an interview with Dr. Ariane Pott from BIOPRO Baden-Württemberg GmbH, Professor Dr. Michael Wink, Director of the Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg, highlighted that plants produce compounds that are effective against microorganisms and that can also be put to good use in the treatment of human diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/fighting-diseases-with-plant-derived-active-compounds
Article - 08/11/2016 Towards at-home genetic testing The ability to detect a broad range of conditions and modifications in human, animal, plant and pathogen genes is highly important in the field of medicine for diagnosing diseases and starting therapy as quickly as possible. Chemists at the University of Konstanz have now developed a genetic test that does not need to be carried out in the laboratory and can be evaluated with the naked eye, similar to a pregnancy test. The test would therefore be…https://www.gesundheitsindustrie-bw.de/en/article/news/towards-at-home-genetic-testing
Press release - 04/11/2016 Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-therapeutics-announces-upcoming-us-patent-issuance-for-mek-treatment-against-viral-diseases
Press release - 04/11/2016 Rentschler expands cGMP manufacturing capacity following increased international demand https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-erweitert-cgmp-produktionskapazitat-wegen-steigender-internationaler-nachfrage
Imaging Methods - 03/11/2016 Using sugar to detect brain tumours An international team of researchers is developing an MRI-based method for the early detection of human brain tumours. The method is called CEST-MRI and it detects elevated glucose concentrations in humour tissues, quantitatively and at high spatial resolution. It does not expose patients to radiation, is non-invasive and relatively inexpensive. https://www.gesundheitsindustrie-bw.de/en/article/news/using-sugar-to-detect-brain-tumours